Clinical trial
A Randomized, Double-blind, Multiple Dose, Parallel-group, Two-arm, Multicenter, Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® (Bimatoprost Ophthalmic Solution) 0.01% in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
NCT05401357 is registered in ClinicalTrials.gov with Amneal Pharmaceuticals, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Multiple Dose, Parallel-group, Two-arm, Multicenter, Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® (Bimatoprost Ophthalmic Solution) 0.01% in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
- Lead sponsor
- Amneal Pharmaceuticals, LLC
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- June 29, 2022
- Completion date
- December 31, 2022
- Enrollment
- 168 (estimated)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.